Artelo Biosciences is advancing ART27.13, a novel drug designed to combat cancer-related weight loss by mimicking the appetite-stimulating effects of cannabis, without the associated psychoactive effects. The drug aims to address cancer cachexia, a debilitating condition affecting a significant proportion of cancer patients, potentially improving their quality of life and overall outcomes.
Targeting Appetite and Muscle Wasting
ART27.13 is designed to activate the CB1 and CB2 receptors in the body, which are known to play a crucial role in appetite control. By selectively targeting these receptors, the drug aims to stimulate hunger and increase food intake in cancer patients experiencing appetite loss. Unlike cannabis, ART27.13 is engineered to have limited access to the brain, thus avoiding the psychoactive effects commonly associated with cannabis use.
Dr. Steven Reich, Artelo’s chief medical officer, noted that research data supports ART27.13's potential as a supportive care therapy, increasing appetite and preventing muscle wasting. This is particularly important as between 60% and 80% of cancer patients experience weight loss, depending on the type of cancer.
Clinical Development and the CAReS Trial
Currently, ART27.13 is being evaluated in the Cancer Appetite Recovery Study (CAReS), a clinical trial assessing its efficacy in restoring appetite, reversing weight loss, and improving the quality of life for cancer patients. The drug is administered as a once-daily capsule.
Dr. Andy Yates, chief scientific officer at Artelo, explained that the drug's action on CB1 and CB2 receptors is key to stimulating appetite. The CAReS study aims to determine the extent to which ART27.13 can effectively restore appetite in patients.
Addressing Unmet Needs in Cancer Care
Cancer cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The condition is associated with poor quality of life, reduced response to cancer treatment, and decreased survival. Current treatment options are limited, highlighting the urgent need for effective interventions.
Dr. Barry Laird, from the University of Edinburgh’s Institute of Genetics and Molecular Medicine and principal investigator in the CARes trial, emphasized the importance of shifting the focus from solely targeting the tumor to providing comprehensive patient care. He stated that ART27.13 represents a new area of therapeutic development with the potential to significantly improve patient outcomes.
Future Implications
If clinical trials prove successful, ART27.13 could become a valuable supportive care option for cancer patients, helping to improve their nutritional status, maintain muscle mass, and enhance their overall well-being. While the drug is still under investigation, early data and expert opinions suggest it holds promise for addressing a significant unmet need in cancer care. According to The Times, the drug could be available as early as 2028 if clinical trials go well.
